Skip to contentJarrett Jennifer — Arcus Biosciences, Inc. insider: 124 transactions · InsiderLensJarrett Jennifer
- Director at Damora Therapeutics, Inc. · on record since Apr 1, 2026
- See Remarks at Damora Therapeutics, Inc. · on record since Apr 1, 2026
- Director at Sagimet Biosciences Inc. · on record since Jun 15, 2026
- Chief Financial Officer at MEDIVATION, INC. · on record since Apr 8, 2016
- Director at ARENA PHARMACEUTICALS INC · on record since Jun 14, 2017
- Director at BOLD ENERGY INC. · on record since Jun 13, 2017
- Director at Syndax Pharmaceuticals Inc · on record since Sep 27, 2018
- Director at Arcus Biosciences, Inc. · on record since Jan 15, 2019
- Director at Surrozen, Inc./DE · on record since Nov 18, 2020
- Chief Operating Officer at Arcus Biosciences, Inc. · on record since Mar 14, 2018
- Former Director at Surrozen, Inc./DE · on record since Aug 13, 2021
- Director at MPM ACQUISITION CORP · on record since May 20, 2022
- Director at Zura Bio Ltd · on record since Mar 21, 2023
Insider trading activity of Jarrett Jennifer
- Transactions on record
- 124
- since Apr 8, 2016
- Open-market buys
- 0
- Open-market sells
- 44
- $11.8M
- Companies traded
- 10
- last filing Jun 22, 2026
Figures computed from official regulatory filings — methodology.
Companies where Jarrett Jennifer has traded
- Zura Bio Ltd4 tx · Jun 22, 2026
- Sagimet Biosciences Inc.3 tx · Jun 15, 2026
- Damora Therapeutics, Inc.2 tx · Apr 1, 2026
- Syndax Pharmaceuticals Inc9 tx · Feb 6, 2026
- Arcus Biosciences, Inc.71 tx · $13.5M · Jan 26, 2026
- MPM ACQUISITION CORP2 tx · $124.8K · Aug 15, 2022
- ARENA PHARMACEUTICALS INC18 tx · Mar 11, 2022
- Surrozen, Inc./DE2 tx · Aug 13, 2021
- BOLD ENERGY INC.8 tx · Jan 15, 2020
- MEDIVATION, INC.
Track record of Jarrett Jennifer
Insufficient history for a statistical track record (fewer than 5 open-market buys).
Transaction history of Jarrett Jennifer
Co-insiders of Jarrett Jennifer
This page republishes public regulatory disclosures. Concerned by this data? Exercise your right to object →
5 tx · Sep 30, 2016
EVNIN LUKEMPM ACQUISITION CORP +1
| Company | Filed | Type | Qty | Price | Value · USD | Src |
|---|
| Jun 22, 2026 | AwardD | 51,000 | 0.00 USD | — | SEC |
| Jun 15, 2026 | AwardD | 39,567 | 0.00 USD | $0 | SEC |
| Apr 1, 2026 | AwardD | 1,500,000 | 0.00 USD | $0 | SEC |
| Apr 1, 2026 | Award | 500,000 | 0.00 USD | $0 | SEC |
| Feb 6, 2026 | Award | 24,000 | 0.00 USD | $0 | SEC |
| Jan 26, 2026 | Award | 31,000 | 0.00 USD | $0 | SEC |
| Jan 26, 2026 | AwardD | 126,000 | 0.00 USD | $0 | SEC |
| Dec 18, 2025 | Sell | -11,225 | 21.88 USD | $245.6K | SEC |
| Dec 18, 2025 | Sell | -9,983 | 22.16 USD | $221.2K | SEC |
| Nov 12, 2025 | Exercise | 50,291 | 1.23 USD | $61.9K | SEC |
| Nov 12, 2025 | ExerciseD | -50,291 | 1.23 USD | $61.9K | SEC |
| Nov 12, 2025 | Sell | -50,291 | 18.97 USD | $954K | SEC |
| Oct 8, 2025 | ExerciseD | -37,792 | 0.00 USD | $0 | SEC |
| Oct 8, 2025 | Exercise | 37,792 | 1.23 USD | $46.5K | SEC |
| Oct 8, 2025 | Sell | -12,500 | 14.54 USD | $181.8K | SEC |
| Oct 8, 2025 | Exercise | 12,500 | 1.23 USD | $15.4K | SEC |
| Oct 8, 2025 | Sell | -37,792 | 15.05 USD | $568.8K | SEC |
| Oct 8, 2025 | ExerciseD | -12,500 | 0.00 USD | $0 | SEC |
| Jun 10, 2025 | AwardD | 27,268 | 0.00 USD | $0 | SEC |
| May 22, 2025 | AwardD | 51,000 | 0.00 USD | $0 | SEC |
| Feb 7, 2025 | Award | 25,000 | 0.00 USD | $0 | SEC |
| Jan 27, 2025 | Award | 50,000 | 0.00 USD | $0 | SEC |
| Jan 27, 2025 | AwardD | 200,000 | 0.00 USD | $0 | SEC |
| Dec 17, 2024 | Other | -27,501 | 16.08 USD | $442.2K | SEC |
| Dec 11, 2024 | AwardD | 117,000 | 0.00 USD | $0 | SEC |